AMG232 (Synonyms: AMG 232;AMG-232) |
Catalog No.GC15828
One-Click Copy Product Info
|
AMG232(AMG 232)는 0.6nM의 IC50을 갖는 p53-MDM2 상호작용의 강력하고 선택적이고 경구적으로 이용 가능한 억제제입니다. AMG232는 0.045nM의 Kd로 MDM2에 결합합니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1352066-68-2
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
AMG-232 is a novel inhibitor of p53-MDM2 with IC50 value of 9.2 nM [1].
Tumor protein p53 (p53) is a very unstable protein with a half-life ranging from 5 to 30 min and participates in a variety of anticancer processes, such as inducing cell apoptosis and inhibiting angiogenesis. Mouse double minute 2 homolog (MDM2), also named as E3 ubiquitin-protein ligase Mdm2, involves in mediating p53 tumor suppressor. It has been conclusively demonstrated p53 is under-expressed in tumor cells [2].
AMG-232 is a potent p53-MDM2 interaction inhibitor and is regarded as a promising drug in clinic. When tested with SJSA-1 tumor cell line, AMG-232 treatment resulted in cell-cycle arrest and inhibition of tumor cell proliferation via binding to MDM2 protein and robustly inducing p53 activity. It was shown that p53-MDM2 bond rang from a Kd of 60 to 700 nM Depending on the length of p53 peptide [3].
In mouse model with SJSA-1 tumor cells subcutaneous xenograft, co-administration of AMG-232 and chemotherapies induced DNA damage and p53 activity which resulted in significantly superior antitumor efficacy and regression through arresting cell growth and inducting apoptosis [3].
References:
[1]. Rew, Y., et al., Discovery of AM-7209, a potent and selective 4-amidobenzoic acid inhibitor of the MDM2-p53 interaction. J Med Chem, 2014. 57(24): p. 10499-511.
[2]. Moll, U.M. and O. Petrenko, The MDM2-p53 interaction. Mol Cancer Res, 2003. 1(14): p. 1001-8.
[3]. Canon, J., et al., The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents. Mol Cancer Ther, 2015. 14(3): p. 649-58.
| Cell experiment [1,2]: | |
|
Cell lines |
SJSA-1, HCT116, and ACHN tumor cell lines |
|
Preparation method |
Soluble in DMSO. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
|
Reacting condition |
0.1, 1, or 10 μmol/L, 24 hours |
|
Applications |
AMG 232 induced p53 signaling with an IC50 of 0.6 ± 0.4 nmol/L. AMG 232 inhibits cell proliferation in p53 WT cell lines. AMG 232 treatment inhibited the growth of cells with IC50 values ranging from 0.1 to 1 μmol/L. AMG 232 caused a dose-dependent accumulation of p53 and increased p21, MDM2, and PUMA proteins in both MDM2-amplified SJSA-1 cells and non–MDM2-amplified HCT116 cells. AMG 232 potently inhibited proliferation of non-MDM2-amplified HCT116 colorectal cells. |
| Animal experiment [1,2]: | |
|
Animal models |
Female athymic nude mice bearing SJSA-1 cells and HCT116 cells |
|
Dosage form |
10 mg/kg, 25 mg/kg, 75 mg/kg; once per day by oral gavage, |
|
Application |
AMG 232 (10 mg/kg, 25 mg/kg, 75 mg/kg, 6 hours) treatment resulted in time- and dose-dependent induction of p21 mRNA in SJSA-1 tumor. AMG 232 treatment also caused a dose-dependent induction of p21, MDM2, and PUMA mRNA in HCT116 tumors. AMG 232 (100 mg/kg, 4 days) treatment caused cell-cycle arrest and induced apoptosis in mice bearing SJSA-1 or HCT116 tumors. AMG 232 (orally once daily) enhanced the antitumor activity of DNA-damaging cytotoxics. AMG 232 displayed robust tumor growth inhibition with an ED50 of 9.1 mg/kg q.d. AMG 232 caused a dose-dependent tumor growth inhibition with an ED50 of 16 mg/kg. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1]. Canon J, Osgood T, Olson S H, et al. The MDM2 inhibitor AMG 232 demonstrates robust anti-tumor efficacy and potentiates the activity of p53-inducing cytotoxic agents[J]. Molecular cancer therapeutics, 2015: molcanther. 0710.2014. [2]. Rew Y, Sun D. Discovery of a small molecule MDM2 inhibitor (AMG 232) for treating cancer[J]. 2014. |
|
| Cas No. | 1352066-68-2 | SDF | |
| Synonyms | AMG 232;AMG-232 | ||
| Chemical Name | 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid | ||
| Canonical SMILES | CC(S(C[C@@H](N([C@H](C1=CC=C(Cl)C=C1)[C@@H](C2=CC=CC(Cl)=C2)C[C@]3(C)CC(O)=O)C3=O)C(C)C)(=O)=O)C | ||
| Formula | C28H35Cl2NO5S | M.Wt | 568.55 |
| Solubility | DMF: 30 mg/ml,DMSO: 30 mg/ml,Ethanol: 30 mg/ml,Ethanol:PBS (pH 7.2)(1:2): 0.33 mg/ml | Storage | Store at -20°C,unstable in solution, ready to use. |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.7589 mL | 8.7943 mL | 17.5886 mL |
| 5 mM | 351.8 μL | 1.7589 mL | 3.5177 mL |
| 10 mM | 175.9 μL | 879.4 μL | 1.7589 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 28 reference(s) in Google Scholar.)